Want to create interactive content? It’s easy in Genially!
Get started free
Market Summary
Luís Simões
Created on October 18, 2024
Start designing with a free template
Discover more than 1500 professional designs like these:
Transcript
Start
YTD 09/2024
Promotional Activity Leaders
- Stodorfen (Teva), new Ibuprofen- Edunix (Aristo Pharma), opioid analgesic- Cuitvar (Teva), for smoking cessation- Kisunla (Lilly), Alzheimer's- Wainua (Astrazeneca), indicated in PAF
- Ebglyss (Almirall), indicated for Atopic Dermatitis- Kelzy (Exeltis), Oral contraceptive- Fluenz (Astrazeneca), Nasal Influenza Vaccine- Fabhalta (Novartis), indicated for HPN- Pyzchiva (Sandoz), Biosimilar- Uzpruvo (Stada), Biosimilar
In Q3 2024, there were 1,081,070 recalled interactions across all medical specialties and pharmacy channel - a slight decrease compared to the previous quarter and the same quarter of the previous year (-1.1% and -0.5%, respectively). There was also an increase in the weight of digital channels (33.4% vs. 31.1% in Q2 2024), following the trend already observed in previous quarters. F2F channels continue to be the most recalled (57.7%), with an emphasis on personal visits. The promotional efforts of the following brands stand out as new:
Q3 2024 Highlights